findmyKOL

Panagiotis Konstantinopoulos, MD

Enriched profile

Director, Mellen and Eisenson Family Center for BRCA and Related Genes; Director of Translational Research, Division of Gynecologic Oncology; Velma Eisenson Endowed Chair for Clinical and Translational Research, Dana-Farber Cancer Institute; Professor of Medicine, Harvard Medical School · Dana-Farber Cancer Institute

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Boston, MA · Northeast · United StatesSpecialtyHematology / OncologyFocusOvarian cancer diagnosis and treatment+4
Active KOLfindmyKOL type: EliteLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding2020–2026

Panagiotis Konstantinopoulos is Director, Mellen and Eisenson Family Center for BRCA and Related Genes; Director of Translational Research, Division of Gynecologic Oncology; Velma Eisenson Endowed Chair for Clinical and Translational Research, Dana-Farber Cancer Institute; Professor of Medicine, Harvard Medical School at Dana-Farber Cancer Institute. OpenAlex indexes 481 publications with 19,507 citations (h-index 66); ClinicalTrials.gov lists 12 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 16 Oct 2026

Panagiotis, MD, is Director, Mellen and Eisenson Family Center for BRCA and Related Genes at Dana-Farber Cancer Institute, Boston, MA. The public record shows 481 publications with 19,507 citations (h-index 66), centered on Ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, Cancer Immunotherapy and Biomarkers. It also documents an investigator role on 12 registered clinical trials, industry payments reported by 13 companies, 2 NIH-funded awards (2020–2026).

  • Most recent indexed publication: 2026 · Nature communications
  • Top research focus: Ovarian cancer diagnosis and treatment
  • 12 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 13 companies

Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Ovarian / Gynecologic Cancer6 trialsEndometrial Neoplasms4 trialsBreast Cancer2 trialsAdenocarcinoma, Clear Cell1 trialCarcinoma, Adenosquamous1 trialUterine Cervical Neoplasms1 trialUterine Neoplasms1 trialVulvar Neoplasms1 trialVaginal Neoplasms1 trialFallopian Tube Neoplasms1 trialCarcinoma, Endometrioid1 trial

Research focus

OpenAlex concept fingerprint
Ovarian cancer diagnosis and treatmentPARP inhibition in cancer therapyCancer Immunotherapy and BiomarkersDNA Repair MechanismsImmune Cell Function and Interaction

Drugs & molecules

across trials, industry payments and publications
Lynparzageneric · OlaparibClinical trials—Industry payments7Publications4Piqraygeneric · AlpelisibClinical trials—Industry payments2Publications3Elaheregeneric · Mirvetuximab soravtansineClinical trials—Industry payments3Publications1Opdivogeneric · NivolumabClinical trials—Industry payments1Publications1Enhertugeneric · TrastuzumabClinical trials—Industry payments2Publications—Fyarrogeneric · SirolimusClinical trials—Industry payments2Publications—Trodelvygeneric · SacituzumabClinical trials—Industry payments2Publications—Imfinzigeneric · DurvalumabClinical trials—Industry payments1Publications—

Works with

trial sponsors and companies reporting payments
GlaxoSmithKline, LLC.Clinical trials—Industry payments22AstraZeneca Pharmaceuticals LPClinical trials—Industry payments21National Cancer Institute (NCI)Clinical trials5Industry payments—Dana-Farber Cancer InstituteClinical trials4Industry payments—E.R. Squibb & Sons, L.L.C.Clinical trials—Industry payments4ImmunoGen, Inc.Clinical trials—Industry payments3Aadi Bioscience, Inc.Clinical trials—Industry payments2Gilead Sciences, Inc.Clinical trials—Industry payments2Acrivon TherapeuticsClinical trials1Industry payments—Alkermes, Inc.Clinical trials—Industry payments1AstraZeneca UK LimitedClinical trials—Industry payments1Beth Israel Deaconess Medical CenterClinical trials1Industry payments—EMD Serono Research & Development Institute, Inc.Clinical trials—Industry payments1Foundation Medicine, Inc.Clinical trials—Industry payments1Kadmon Corporation LLCClinical trials—Industry payments1Novartis Pharma AGClinical trials—Industry payments1Novartis Pharmaceuticals CorporationClinical trials—Industry payments1Panagiotis Konstantinopoulos, MD, PhDClinical trials1Industry payments—

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
481publications

Distinct works indexed by OpenAlex, matched via ORCID; 33 in PubMed.

19,507citations

Total citations across indexed works.

66h-index

Hirsch index (OpenAlex). i10-index 166.

Clinical & industry

trials, payments and federal funding
12clinical trials

Investigator role on registered studies.

View trials ↓
13companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
2NIH grants · 2020–2026

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 16 Oct 2026

Listed as an investigator on 12 registered studies on ClinicalTrials.gov. The most recent:

All 12 trial records: search, sort and filter.Explore →

Industry payments

Updated 16 Oct 2026

13 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

All 20 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    54.8%
    Poly(ADP-Ribose) Polymerase Inhibitor54.8%
    Lynparza65%Zejula35%
    Part D<11 patients

  • Nervous system

    25.8%
    Phenothiazine25.8%
    Prochlorperazine Maleate100%
    Part D≥13 patients

  • Metabolism & gastrointestinal

    19.4%
    Serotonin-3 Receptor Antagonist19.4%
    Ondansetron Hcl100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 16 Oct 2026

2 NIH research awards on record, funded 2020–2026 per NIH RePORTER. The latest:

All 16 award records: search, sort and filter.Explore →

Congress activity

Updated 16 Oct 2026

57 congress contributions (2011–2026) across AACR, ASCO, ESMO per OpenAlex. The most recent:

All 57 congress records: search, sort and filter.Explore →

Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.

Publications

Updated 16 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

All 33 publications: search, sort and filter.Explore →

Most-cited works

by citation count (OpenAlex)
  1. 01
    Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
    963 citations2015
    doi.org ↗
  2. 02
    Replication fork stability confers chemoresistance in BRCA-deficient cells
    932 citations2016
    doi.org ↗
  3. 03
    Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair
    889 citations2015
    doi.org ↗
  4. 04
    Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1
    685 citations2015
    doi.org ↗
  5. 05
    DNA Damage and Repair Biomarkers of Immunotherapy Response
    667 citations2017
    doi.org ↗
All 481 cited works: search, sort and filter.Explore →

Network

Updated 16 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Ursula A. Matulonis240Joyce F. Liu151Nabihah Tayob109Alan D. D’Andrea99Elizabeth H. Stover78Geoffrey I. Shapiro76Su–Chun Cheng58Madeline Polak52Elizabeth M. Swisher52Niya Xiong50Bose Kochupurakkal50Neil S. Horowitz49Catherine J. Wu47Courtney Qi47Donna Neuberg46Derin B. Keskin44MacLean Sellars44Min Liu43Vipheaviny Chea43Julia Fasse43Isabel Carulli43Laura Frackiewicz43Livius Penter43Guanglan Zhang43Kenneth J. Livak43Anna Tarren43Teddy Huang43Jennifer Curtis42Phuong A. Le42Anniina Färkkilä42Shuqiang Li40Gerburg M. Wulf37Susana M. Campos37Carolyn Krasner36Alexi A. Wright34Chunyu Yang34Dipanjan Chowdhury33Eric P. Winer31Stephen A. Cannistra31Felipe Batalini29

Online presence

Updated 16 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/panagiotis-konstantinopoulos-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
  • ResearchGate

    researchgate.net/scientific-contributions/Panagiotis-A-Konstantinopoulos-2209328555

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗

Mentions by others

where others cite or feature them
  • LinkedIn

    linkedin.com/posts/dana-farber-cancer-institute_panos-konstantinopoulos-md-phd-director-activity-7272762126534946816-T1_i

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
  • Other

    physicianresources.dana-farber.org/videos/panos-konstantinopoulos-md-phd-shares-results-of-a-phase-2-endometrial-cancer-study-at-2022-sgo

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physicianresources.dana-farber.org ↗
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 16 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Board Certification

    Medical Oncology

    2008
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
  • Board Certification

    Internal Medicine

    2005
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
  • MD

    University of Patras Medical School, Greece

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
  • PhD

    University of Patras, Greece

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
  • Master's degree in Clinical Investigation

    Harvard Medical School and MIT Department of Health Sciences and Technology

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗

Editorial & leadership roles

journal and society appointments
  • Director

    Mellen and Eisenson Family Center for BRCA and Related Genes, Dana-Farber Cancer Institute

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
  • Director of Translational Research

    Division of Gynecologic Oncology, Dana-Farber Cancer Institute

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
  • Editorial Board Member

    Journal of Clinical Oncology

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ascopubs.org ↗
  • Co-Chair

    Dana-Farber/Harvard Cancer Center (DFHCC) Audit Committee

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dana-farber.org ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution
  • Investigator

    Breast Cancer Research Foundation (BCRF), since 2018

    2018
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bcrf.org ↗
  • Co-Chair

    NRG Oncology Developmental Therapeutics (Translational Science) Committee

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dana-farber.org ↗

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.